What caused MCK's Q2 2025 earnings to exceed forecasts?

McKesson's Q2 2025 earnings exceeded forecasts due to strong performance in the U.S. Pharmaceutical segment, driven by increased prescription volumes and the onboarding of a new strategic partner. Additionally, the Prescription Technology Solutions segment contributed to the growth, with a 11% increase in revenue. The company's strategic investments in technology and modernization initiatives are expected to generate $250 million in benefits over the next five years. These factors, combined with the Medical-Surgical Solutions segment's 4% increase in revenue, contributed to McKesson's overall revenue exceeding expectations.

|code|Ticker|Name|Date|EPS Surprise|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|MCK|MCK.N|McKesson|2025 Q1|0.67|7|169|
|MCK|MCK.N|McKesson|2025 Q2|0.15|1.87|169|